Geron (GERN) Net Cash Flow (2010 - 2026)
Geron (GERN) posted Net Cash Flow of -$8.6 million for Q1 2026, down 1485.48% sequentially from -$544000.0 in Q4 2025, and down 282.89% YoY from $4.7 million in Q1 2025.
Geron (GERN) Net Cash Flow (2010 - 2026) Analysis & Trends
Geron has reported Net Cash Flow for 17 years, with the latest figure at -$8.6 million in Q1 2026.
- Quarterly Net Cash Flow fell 282.89% year-over-year to -$8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.9 million (up 85.88% YoY) and the FY2025 annual result came in at -$1.5 million, down 115.62% from the prior year.
- Net Cash Flow eased to -$8.6 million in Q1 2026 per GERN's latest filing, from -$544000.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at $119.8 million in Q1 2024 and troughed at -$72.8 million in Q2 2024.
- A 5-year average of -$2.1 million and a median of -$4.3 million in 2022 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2026: Net Cash Flow jumped 1677.36% in 2023, then tumbled 282.89% in 2026.
- Over 5 years, Net Cash Flow stood at -$4.3 million in 2022, then jumped by 1034.68% to $39.9 million in 2023, then tumbled by 53.13% to $18.7 million in 2024, then slumped by 102.91% to -$544000.0 in 2025, then sank by 1485.48% to -$8.6 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$8.6 million, -$544000.0, and $314000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | -6.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.15 Mn |
| Jun 30, 2026 | -6.15 Mn |
| Mar 31, 2026 | -8.63 Mn |
| Mar 31, 2026 | -8.63 Mn |
| Dec 31, 2025 | -544,000.00 |
| Dec 31, 2025 | -544,000.00 |
| Sep 30, 2025 | 314,000.00 |
| Sep 30, 2025 | 314,000.00 |
| Jun 30, 2025 | -6.01 Mn |
| Jun 30, 2025 | -6.01 Mn |
| Mar 31, 2025 | 4.72 Mn |
| Mar 31, 2025 | 4.72 Mn |
| Dec 31, 2024 | 18.71 Mn |
| Dec 31, 2024 | 18.71 Mn |
| Sep 30, 2024 | -55.92 Mn |
| Sep 30, 2024 | -55.92 Mn |
| Jun 30, 2024 | -72.79 Mn |
| Jun 30, 2024 | -72.79 Mn |
| Mar 31, 2024 | 119.75 Mn |
| Mar 31, 2024 | 119.75 Mn |